Bifidobacterium Breve for Weight Management

Research suggests that evidence directly linking Bifidobacterium breve to weight management in humans remains limited, with only one relevant randomized controlled trial in the available literature — a 12-week study in overweight and obese adults that found a multi-strain probiotic containing B. breve produced modest but statistically significant reductions in BMI, body weight, and waist-to-hip ratio compared to placebo, though changes in body fat and metabolic markers like blood sugar and lipids did not reach significance. The remaining studies in this set are not directly relevant to weight management, as one examined B. breve's role in countering obesity-related immune suppression in a mouse cancer model, and another used computational modeling to explore infant gut microbiome effects on a genetic metabolic disorder. The single human trial, while encouraging in its direction, was relatively small, used a multi-strain product rather than B. breve alone, and had a notable dropout rate, making it difficult to draw firm conclusions about B. breve's independent contribution to weight outcomes. Studies indicate that more targeted, well-powered human trials are needed before strong conclusions can be drawn about this strain's role in weight management.